Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph
+ALL) develops owing to the formation of
BCR-ABL tyrosine kinase due to a reciprocal translocation between chromosomes 9 and 22. Although Ph
+ALL treated by conventional chemotherapy reportedly has a poor prognosis, imatinib mesylate has been shown to markedly improve both complete remission (CR) rates and overall survival rates. Therefore, we retrospectively investigated the outcome of chemotherapy combined with a tyrosine kinase inhibitor (TKI) in 5 patients with newly diagnosed Ph
+ALL (median age, 46 years; 2 males and 3 females) treated in the past decade. According to the results, the CR rate was 100% and 3 of the 5 patients survived without progression of the disease. TKI showed remarkable efficacy in these patients. A majority of the Ph
+ALL patients achieved CR during the TKI treatment, but some patients relapsed with the emergence of imatinib resistance. Therefore, we should select the best TKI among several available drugs, and establish the best combination of TKI and stem cell transplantation to improve the clinical outcome of Ph
+ALL. It is important to simultaneously monitor
BCR-ABL chimera while analyzing the
ABL gene mutation.
View full abstract